A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of ReoCure as Monotherapy and in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours

开始日期2020-08-27

申办/合作机构

ViroCure, Inc.初创企业

100 项与 ViroCure, Inc. 相关的临床结果

登录后查看更多信息

0 项与 ViroCure, Inc. 相关的专利（医药）

登录后查看更多信息

项与 ViroCure, Inc. 相关的文献（医药）

2021-07-01·Cancer Research

Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer

作者: Kong, So Jung ; Lee, Won Suk ; Kim, Jeong Hun ; Kim, Chan ; Lee, Yu Seong ; Song, Ki-Hoon ; Lee, Hye Jin ; Lee, Seung Joon ; Lee, Yeon-Sook ; Chon, Hong Jae ; Kang, Beodeul ; Gansukh, Enkhtaivan ; Yang, Hannah

AbstractIntroduction: Reoviruses are replication-competent and selectively infect and destroy cancer cells. Although the most common route of oncolytic virotherapy is intratumoral or intravenous administration, these routes are often not clinically feasible because of tumor inaccessibility, tumor multiplicity, and systemic toxicities. Here, we developed an orally available oncolytic reovirus, RC402, to elicit potent anti-tumor immune responses without the above mentioned limitations and thereby maximize the efficacy of PD-1 immune checkpoint blockade in colon cancer.Method: MC38 or CT26 colon cancer-bearing immunocompetent mice were treated with RC402 and/or anti-PD-1 antibody. Tumor growth was monitored after treatment and comprehensively analyzed by flow cytometry and/or multiplex tissue imaging.Results: RC402 treatment effectively delayed tumor growth regardless of the route of administration (per os as well as intratumorally). In particular, orally administered RC402 was well tolerated without gross toxicity and interacted with intestinal immune cells, eliciting adaptive T cell responses within intestinal lymphoid organs such as Peyer's patch. Most of the RC402 was cleared in the gastrointestinal tract within 10 days of the first treatment, and it was not detectable in the blood stream or major organs after oral administration. However, RC402 selectively induced strong and durable anti-tumor immunity in distant tumor tissues. Oral RC402 monotherapy markedly increased CD8+ cytotoxic T cells and decreased CD4+CD25+Foxp3+ regulatory T cells in distant colon cancers, while there were no significant changes in tumor-associated myeloid cells. Finally, oral RC402 treatment cooperated with anti-PD-1 blockade to further suppress colon cancer growth and augment anti-tumor immunity within the tumor microenvironment, leading to complete regression of tumors and survival benefit of tumor-bearing mice.Conclusion: Our study demonstrates that orally available oncolytic reovirus, RC402, could induce potent anti-cancer immune responses and effectively suppress colon cancer progression in combination with anti-PD-1 blockade.Citation Format: Chan Kim, Hong Jae Chon, Hye Jin Lee, Won Suk Lee, Hannah Yang, Jeong Hun Kim, So Jung Kong, Yu Seong Lee, Seung Joon Lee, Enkhtaivan Gansukh, Ki-Hoon Song, Yeon-Sook Lee, Beodeul Kang. Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1914.

Frontiers in Molecular Biosciences3区 · 生物学

Structure of New Binary and Ternary DNA Polymerase Complexes From Bacteriophage RB69

3区 · 生物学

ArticleOA

作者: An, Jun Yop ; Wang, Jimin ; Youn, Hyung-Seop ; Park, Jongseo ; Lee, Youngjin ; Eom, Soo Hyun

DNA polymerase plays a critical role in passing the genetic information of any living organism to its offspring. DNA polymerase from enterobacteria phage RB69 (RB69pol) has both polymerization and exonuclease activities and has been extensively studied as a model system for B-family DNA polymerases. Many binary and ternary complex structures of RB69pol are known, and they all contain a single polymerase-primer/template (P/T) DNA complex. Here, we report a crystal structure of the exonuclease-deficient RB69pol with the P/T duplex in a dimeric form at a resolution of 2.2 Å. The structure includes one new closed ternary complex with a single divalent metal ion bound and one new open binary complex in the pre-insertion state with a vacant dNTP-binding pocket. These complexes suggest that initial binding of the correct dNTP in the open state is much weaker than expected and that initial binding of the second divalent metal ion in the closed state is also much weaker than measured. Additional conformational changes are required to convert these complexes to high-affinity states. Thus, the measured affinities for the correct incoming dNTP and divalent metal ions are average values from many conformationally distinctive states. Our structure provides new insights into the order of the complex assembly involving two divalent metal ions. The biological relevance of specific interactions observed between one RB69pol and the P/T duplex bound to the second RB69pol observed within this dimeric complex is discussed.

Scientific Reports

Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy

Article

作者: Park, Minji ; Song, Ki-Hoon ; Park, Jeehun ; Park, Dong Guk ; Lim, Joung Eun ; Kim, Hyun-Young ; Jeong, Byong Chang ; Cho, Duck ; Lim, Yuree ; Lee, Seung-Hwan ; Lee, Mijeong ; Koh, Seung Kwon ; Kim, Sang-Ki

AbstractIntravesical treatment using either reovirus or natural killer (NK) cells serves as an efficient strategy for the treatment of bladder cancer cells (BCCs); however, corresponding monotherapies have often shown modest cytotoxicity. The potential of a locoregional combination using high-dose reovirus and NK cell therapy in an intravesical approach has not yet been studied. In this study, we evaluated the effectiveness of reoviruses and expanded NK cells (eNK) as potential strategies for the treatment of bladder cancer. The anti-tumor effects of mono-treatment with reovirus type 3 Dearing strain (RC402 and RP116) and in combination with interleukin (IL)-18/-21-pretreated eNK cells were investigated on BCC lines (5637, HT-1376, and 253J-BV) using intravesical therapy to simulate in vitro model. RP116 and IL-18/-21-pretreated eNK cells exhibited effective cytotoxicity against grade 1 carcinoma (5637 cells) when used alone, but not against HT-1376 (grade 2 carcinoma) and 253J-BV cells (derived from a metastatic site). Notably, combining RP116 with IL-18/-21-pretreated eNK cells displayed effective cytotoxicity against both HT-1376 and 253J-BV cells. Our findings underscore the potential of a combination therapy using reoviruses and NK cells as a promising strategy for treating bladder cancer.

项与 ViroCure, Inc. 相关的新闻（医药）

2021-04-15

·GlobeNewswire

Global Oncolytic Virus Therapies Market: Focus on

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region, and Competitive Landscape - Analysis and Forecast, 2020-2030" - • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR• Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV• Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)• Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)Regional Segmentation• North America: U.S.• Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)• Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)Growth Drivers• Increasing Incidence of Cancer• Rising Number of Clinical Trials• Increasing Research Funding from National Cancer Institute• Increasing Adoption of Inorganic Growth Strategies in the MarketMarket Challenges• High Cost of Therapy• Lack of Therapy-Specific AssaysMarket Opportunities• Opportunities in the Emerging Economies• Drug Approvals and Strong Pipeline of Oncolytic Virus TherapiesKey Companies ProfiledAmgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030?• Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? • What is the COVID-19 impact on the global oncolytic virus therapies market?• Which companies are anticipated to be highly disruptive in the future, and why?• What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?• What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?• What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?• How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: o Commercialized Therapies o Pipeline Therapies o Type of Virus o Application o RegionMarket OverviewOncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body.These therapies aim at modifying genetic material for the treatment of a disease.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”.Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth.Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay.Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.Countries Covered• North America• U.S.• Europe• U.K.• Latvia• Georgia• Armenia• Germany• France• Italy• Rest-of-Europe• Asia-Pacific• China• Japan• Rest-of-APACRead the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

基因疗法

100 项与 ViroCure, Inc. 相关的药物交易

登录后查看更多信息

100 项与 ViroCure, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

RC-402	结直肠癌肝转移更多	临床1期
NK cell + OV(ViroCure)	膀胱癌更多	临床前
RP-116	肉瘤更多	临床前
MC-509	肺癌更多	临床前
SC-717	肿瘤更多	临床前